in this issue
Regions :: Western Europe :: Switzerland
Lonza and Organobalance Sign License Agreement
12:31 AM MDT | April 19, 2011 | Deepti Ramesh
Lonza says it has signed a worldwide exclusive license agreement with Organobalance (Berlin, Germany), in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by Organobalance, the probiotic strain acts against Helicobacter pylori (H. pylori), which has been implicated as a common cause of peptic ulcers and gastritis. In close cooperation with industry partners, Organobalance develops biological products in the fields of pharmaceutics, preventive health care, nutrition and cosmetics. Organobalance...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee